In a recent research report by Maximize Market Research, the Advanced Therapy Medicinal Products Market is expected to surpass US $ 21.3 Bn by the year 2027, from the US $ 9.6 Bn in 2020.

Gene therapy, somatic cell treatment, and tissue-engineered products are all examples of advanced therapy medical products (ATMPs). These treatments are predicted to provide significant health advantages while also having a significant financial influence on the pharmaceutical industry. ATMPs represent a fast-growing field of interest.

Kymriah is a CAR-T therapy for individuals with B-cell acute lymphoblastic leukemia and relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Breyanzi, a novel CAR-T cell treatment for R/R B-Cell Lymphoma developed by Bristol Myers Squibb, received clearance from Japan’s Ministry of Health, Labor, and Welfare (MHLW) in March 2021. As a result, investment flows have migrated toward the development of CAR-T therapies, resulting in considerable segment growth.

The Asia Pacific region is estimated to gain significant market growth in the coming years. The dominating countries of Asia Pacific are India, China, and Japan. China is leading in the Asia Pacific and has a potential market for advanced therapies and ranks second in the world in terms of cell and gene therapy market. Further, government initiatives in the regions and expenditure by the market players are estimated to lead towards market expansion.

Europe is estimated to grow at a significant level in the forecast period. Regulation (EC) 1394/2007, which took effect on December 30, 2008, established an administrative framework for such products in Europe. The guideline established an integrated advertising approval process as the appropriate course for approving the market for advanced treatment medical items. Furthermore, it established the Committee for Advanced Therapies (CAT) inside the European Medicines Agency (EMA), which is responsible for reviewing the quality, safety, and viability of cutting-edge therapies that expand the market in a given region.

Despite a huge decline in the sales of products during the initial phase of pandemic spread and lockdown restrictions all over the region, the market is observed to pick up a quick pace for registering a CAGR of almost more than 13.2 %, during the tenure of 2021 – 2027.

The report published by Maximize encompasses the market dynamics, which could affect the market growth of the Advanced Therapy Medicinal Products Market in the region, the Value – Chain Analysis, and the PORTER’s analysis for the Advanced Therapy Medicinal Products Market at a global level. The study is associated based on major segments and further into sub-segments, Therapy Type (Cell Therapy, CAR-T Therapy, Gene Therapy, Tissue Engineered Product) to forecast the market size by value; also includes the analysis of past market dynamics from 2016 – 2019, considering 2020 as the base year.

Lastly, the market research report provides a regional comparison and a complete country-level analysis for the Technology trends, along with the major key players- Spark Therapeutics, Inc.; Bluebird Bio, Inc.; Novartis AG; UniQure N.V.; Celgene Corporation; Gilead Lifesciences, Inc.; Kolon TissueGene, Inc.; JCR Pharmaceuticals Co., Ltd.; MEDIPOST; Vericel Corporation; PHARMICELL Co., Ltd; Organogenesis Inc.

You can browse the market data Tables and Figures spread through a comprehensive research report and in-depth TOC on the “Global Advanced Therapy Medicinal Products Market.”

https://www.maximizemarketresearch.com/market-report/global-advanced-therapy-medicinal-products-market/119588/

Contact:

MAXIMIZE MARKET RESEARCH PVT. LTD.

3rd Floor, Office no. 18.4,

Navale IT Zone Phase-2,

Mumbai -Bangalore bypass highway,

Pune- 18.411018.41

Maharashtra, India

+91 9607195908

Leave a Replay

Your email address will not be published. Required fields are marked *

*
*